Sarepta Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming investor conferences:

• Leerink Partners Global Biopharma Conference on Mon., March 11, 2024, at 10:00 a.m. E.T at the Fontainebleau Hotel in Miami, Fla.
• Barclays 26th Annual Global Healthcare Conference on Tue., March 12, 2024, at 3:05 p.m. E.T. at the Loews Miami Beach Hotel in Miami, Fla.

The presentations will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240304022051/en/

Investor Contact:
Ian Estepan, 617-274-4052
[email protected]

Media Contact:
Tracy Sorrentino, 617-301-8566
[email protected]

Source: Sarepta Therapeutics, Inc.

You May Also Be Interested In

• Halliburton Announces Dividend
• Latest Crypto News: Bitcoin Rips Past $77K, Cardano Turns Bullish – Is Apeing Whitelist the Next Move for Traders? 
• Tallgrass Announces Open Season for the Seahorse Pipeline